BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kempf W, Pfaltz K, Vermeer MH, Cozzio A, Ortiz-Romero PL, Bagot M, Olsen E, Kim YH, Dummer R, Pimpinelli N, Whittaker S, Hodak E, Cerroni L, Berti E, Horwitz S, Prince HM, Guitart J, Estrach T, Sanches JA, Duvic M, Ranki A, Dreno B, Ostheeren-Michaelis S, Knobler R, Wood G, Willemze R. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 2011;118:4024-35. [PMID: 21841159 DOI: 10.1182/blood-2011-05-351346] [Cited by in Crossref: 245] [Cited by in F6Publishing: 198] [Article Influence: 22.3] [Reference Citation Analysis]
Number Citing Articles
1 Clemens MW, Horwitz SM. NCCN Consensus Guidelines for the Diagnosis and Management of Breast Implant-Associated Anaplastic Large Cell Lymphoma. Aesthetic Surgery Journal 2017;37:285-9. [DOI: 10.1093/asj/sjw259] [Cited by in Crossref: 106] [Cited by in F6Publishing: 93] [Article Influence: 21.2] [Reference Citation Analysis]
2 Vu K, Ai W. Update on the Treatment of Anaplastic Large Cell Lymphoma. Curr Hematol Malig Rep 2018;13:135-41. [DOI: 10.1007/s11899-018-0436-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
3 Floyd EG, Burns TF, Linos K, LeBlanc RE, Carter JB, Jarvis LA, Lansigan F. Combined Modality Treatment With Brentuximab Vedotin and Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: A Case Report. J Hematol 2019;8:132-6. [PMID: 32300458 DOI: 10.14740/jh534] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Gastaud L, Rossignol B, Peyrade F, Ré D, Thariat J, Thyss A, Doyen J. Place de la radiothérapie dans la prise en charge des lymphomes malins non hodgkiniens. Cancer/Radiothérapie 2016;20:236-47. [DOI: 10.1016/j.canrad.2016.01.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
5 Di Napoli A, De Cecco L, Piccaluga PP, Navari M, Cancila V, Cippitelli C, Pepe G, Lopez G, Monardo F, Bianchi A, D'Amore ESG, Gianelli U, Facchetti F, Berti E, Bhagat G. Transcriptional analysis distinguishes breast implant-associated anaplastic large cell lymphoma from other peripheral T-cell lymphomas. Mod Pathol 2019;32:216-30. [PMID: 30206415 DOI: 10.1038/s41379-018-0130-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
6 Nhu QM, Du EZ, Kiyani A, Frenette CT. A rare localised nasal CD30+ primary cutaneous T-cell lymphoma following liver transplantation. BMJ Case Rep 2017;2017:bcr-2017-221028. [PMID: 29103006 DOI: 10.1136/bcr-2017-221028] [Reference Citation Analysis]
7 Melchers RC, Willemze R, van de Loo M, van Doorn R, Jansen PM, Cleven AHG, Solleveld N, Bekkenk MW, van Kester MS, Diercks GFH, Vermeer MH, Quint KD. Clinical, Histologic, and Molecular Characteristics of Anaplastic Lymphoma Kinase-positive Primary Cutaneous Anaplastic Large Cell Lymphoma. Am J Surg Pathol 2020;44:776-81. [PMID: 32412717 DOI: 10.1097/PAS.0000000000001449] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
8 Henderson Berg MH, Davison K, Popradi G. Real-world effectiveness of brentuximab vedotin in the treatment of CD30-positive cutaneous T-cell lymphoma: a single-centre retrospective review. Br J Dermatol 2021. [PMID: 34608632 DOI: 10.1111/bjd.20786] [Reference Citation Analysis]
9 Stranzenbach R, Stadler R. Kombination aus Brentuximab-Vedotin und hautspezifischen Therapien verlängert bei Patienten mit kutanem T-Zell-Lymphom die Zeit bis zur nächsten Therapieeskalation. J Dtsch Dermatol Ges 2021;19:383-8. [PMID: 33709582 DOI: 10.1111/ddg.14342_g] [Reference Citation Analysis]
10 Bajor-Dattilo EB, Pittaluga S, Jaffe ES. Pathobiology of T-cell and NK-cell lymphomas. Best Pract Res Clin Haematol 2013;26:75-87. [PMID: 23768642 DOI: 10.1016/j.beha.2013.04.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
11 Stranzenbach R, Dippel E, Schlaak M, Stadler R. Brentuximab vedotin in CD30 + cutaneous lymphoma: How do we treat, how shall we treat? A review of the literature. Br J Dermatol 2017;177:1503-9. [DOI: 10.1111/bjd.15801] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
12 Abdulla FR, Zhang W, Wu X, Honda K, Qin H, Cho H, Querfeld C, Zain J, Rosen ST, Chan WC, Parekh V, Song JY. Genomic Analysis of Cutaneous CD30-Positive Lymphoproliferative Disorders. JID Innov 2022;2:100068. [PMID: 34977845 DOI: 10.1016/j.xjidi.2021.100068] [Reference Citation Analysis]
13 Stowman AM, Hsia L, Kanner WA, Mahadevan MS, Bullock GC, Patterson JW. Multiple cutaneous lymphoproliferative disorders showing a retained tumor clone by T-cell receptor gene rearrangement analysis: a case series of four patients and review of the literature. Int J Dermatol 2016;55:e62-71. [DOI: 10.1111/ijd.12847] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
14 Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, Jaffe ES. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019;133:1703-14. [PMID: 30635287 DOI: 10.1182/blood-2018-11-881268] [Cited by in Crossref: 298] [Cited by in F6Publishing: 244] [Article Influence: 99.3] [Reference Citation Analysis]
15 Turner SD, Lamant L, Kenner L, Brugières L. Anaplastic large cell lymphoma in paediatric and young adult patients. Br J Haematol 2016;173:560-72. [PMID: 26913827 DOI: 10.1111/bjh.13958] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 9.5] [Reference Citation Analysis]
16 Kubo N, Itoh M, Watanabe Y, Nobeyama Y, Asahina A. Regression of CD30-positive large cell transformation arising on patch lesion of early mycosis fungoides. Clin Case Rep 2020;8:2418-22. [PMID: 33363752 DOI: 10.1002/ccr3.3171] [Reference Citation Analysis]
17 D'Incan M, Ingen-Housz-Oro S, Beylot-Barry M, Joly P, Grange F, Quereux G, Templier I, Ram-Wolff C, Adamski H, Lambert C, Descours C. Locoregional nodal extension does not impair prognosis of primary cutaneous anaplastic lymphomas. Br J Dermatol 2021;184:356-8. [PMID: 32810288 DOI: 10.1111/bjd.19495] [Reference Citation Analysis]
18 De Souza A, Tinguely M, Pfaltz M, Burghart DR, Kempf W. Loss of expression of 5-hydroxymethylcytosine in CD30-positive cutaneous lymphoproliferative disorders: Loss of expression of 5-hmC in CD30. J Cutan Pathol 2014;41:901-6. [DOI: 10.1111/cup.12411] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
19 Fernández-Nieto D, Moreno-Moreno E, Fernández-Guarino M. [Fast-evolving necrotic ulcer]. Aten Primaria 2019;51:656-7. [PMID: 30987855 DOI: 10.1016/j.aprim.2019.02.002] [Reference Citation Analysis]
20 Mccurdy O, Mccormack C, Ritchie D, Prince HM. Exacerbation of lymphomatoid papulosis during rituximab therapy: LyP exacerbated by rituximab. Australasian Journal of Dermatology 2014;55:e1-3. [DOI: 10.1111/ajd.12002] [Cited by in Crossref: 7] [Article Influence: 0.7] [Reference Citation Analysis]
21 Moy A, Sun J, Ma S, Seminario-vidal L. Lymphomatoid Papulosis and Other Lymphoma-Like Diseases. Dermatologic Clinics 2019;37:471-82. [DOI: 10.1016/j.det.2019.05.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Kaplan JB, Guitart J, Giles FJ. Targeted therapies for cutaneous T-cell lymphomas. Expert Review of Hematology 2014;7:481-93. [DOI: 10.1586/17474086.2014.942279] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
23 Wieser I, Tetzlaff MT, Torres Cabala CA, Duvic M. Primary cutaneous CD30 + lymphoproliferative disorders: CME Article. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2016;14:767-82. [DOI: 10.1111/ddg.13117] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
24 Shahriari N, Ferenczi K, Heald PW. Breast implant-associated anaplastic large cell lymphoma: A review and assessment of cutaneous manifestations. Int J Womens Dermatol 2017;3:140-4. [PMID: 28831423 DOI: 10.1016/j.ijwd.2017.05.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
25 Iuliano A, Fossataro F, Laezza MP, Lanni V, Mascolo M, Varricchio S, Uccello G, Tranfa F, Strianese D. Primary cutaneous anaplastic large-cell lymphoma of the eyelid: report of two cases and review of the literature. Orbit 2020;:1-7. [PMID: 32998605 DOI: 10.1080/01676830.2020.1826543] [Reference Citation Analysis]
26 Fujii K, Kanekura T. Surgical excision: An option for a resectable lesion of cutaneous type adult T-cell leukemia/lymphoma. J Dermatol 2021. [PMID: 34747058 DOI: 10.1111/1346-8138.16221] [Reference Citation Analysis]
27 Sarfraz H, Gentille C, Ensor J, Wang L, Wong S, Ketcham MS, Joshi J, Pingali SRK. Primary cutaneous anaplastic large-cell lymphoma: a review of the SEER database from 2005 to 2016. Clin Exp Dermatol 2021. [PMID: 34081802 DOI: 10.1111/ced.14777] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Peterson E, Weed J, Lo Sicco K, Latkowski JA. Cutaneous T Cell Lymphoma: A Difficult Diagnosis Demystified. Dermatol Clin 2019;37:455-69. [PMID: 31466586 DOI: 10.1016/j.det.2019.05.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
29 Scarisbrick JJ. New drugs in cutaneous T-cell lymphomas. Current Opinion in Oncology 2016;28:384-9. [DOI: 10.1097/cco.0000000000000311] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
30 Kempf W. Cutaneous CD30-Positive Lymphoproliferative Disorders. Surgical Pathology Clinics 2014;7:203-28. [DOI: 10.1016/j.path.2014.02.001] [Cited by in Crossref: 46] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
31 Bruijn M, Horváth B, van Voorst Vader P, Willemze R, Vermeer M. Recommendations for treatment of lymphomatoid papulosis with methotrexate: a report from the Dutch Cutaneous Lymphoma Group. Br J Dermatol 2015;173:1319-22. [DOI: 10.1111/bjd.13920] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
32 Stranzenbach R. How do we treat cutaneous T-cell lymphoma? Ital J Dermatol Venerol 2021;156:534-44. [PMID: 32938164 DOI: 10.23736/S2784-8671.20.06606-7] [Reference Citation Analysis]
33 Seçkin D, Barete S, Euvrard S, Francès C, Kanitakis J, Geusau A, Del Marmol V, Harwood CA, Proby CM, Ali I, Güleç AT, Durukan E, Lebbé C, Alaibac M, Laffitte E, Cooper S, Bouwes Bavinck JN, Murphy GM, Ferrándiz C, Mørk C, Cetkovská P, Kempf W, Hofbauer GF. Primary cutaneous posttransplant lymphoproliferative disorders in solid organ transplant recipients: a multicenter European case series. Am J Transplant 2013;13:2146-53. [PMID: 23718915 DOI: 10.1111/ajt.12281] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 5.8] [Reference Citation Analysis]
34 Ortiz-Romero PL. Targeting KIR3DL2 in primary cutaneous anaplastic large cell lymphomas. Br J Dermatol 2016;175:246-7. [PMID: 27535600 DOI: 10.1111/bjd.14783] [Reference Citation Analysis]
35 Kluk J, Child F, Robson A. Lymphomatoid papulosis with 6p25.3 rearrangement: a further case of the newly described variant. Br J Dermatol 2014;171:1590-2. [DOI: 10.1111/bjd.13092] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
36 Larocca CA, LeBoeuf NR. Overview of Cutaneous T-Cell Lymphomas. Hematol Oncol Clin North Am 2019;33:669-86. [PMID: 31229162 DOI: 10.1016/j.hoc.2019.04.004] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
37 Klemke CD. Cutaneous lymphomas. J Dtsch Dermatol Ges 2014;12:7-28; quiz 29-30. [PMID: 24393310 DOI: 10.1111/ddg.12237] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
38 Stainthorpe A, Fleeman N, Houten R, Chaplin M, Boland A, Beale S, Dundar Y, McEntee J, Syndikus I. Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoecon Open 2020;4:563-74. [PMID: 32207075 DOI: 10.1007/s41669-020-00203-0] [Reference Citation Analysis]
39 Brown RA, Fernandez-Pol S, Kim J. Primary cutaneous anaplastic large cell lymphoma. J Cutan Pathol 2017;44:570-7. [PMID: 28342276 DOI: 10.1111/cup.12937] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
40 Newland KM, McCormack CJ, Twigger R, Buelens O, Hughes CF, Lade S, Dickinson M, Yap LM, Ryan G, Prince HM. The efficacy of methotrexate for lymphomatoid papulosis. J Am Acad Dermatol 2015;72:1088-90. [PMID: 25981010 DOI: 10.1016/j.jaad.2015.03.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
41 Gru AA, Voorhess PJ. A Case of ALK+ Anaplastic Large-Cell Lymphoma With Aberrant Myeloperoxidase Expression and Initial Cutaneous Presentation. The American Journal of Dermatopathology 2018;40:519-22. [DOI: 10.1097/dad.0000000000001061] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Xue D, Li X, Ren Y, Liu Q, Yen Y, Xue L. Primary Cutaneous Anaplastic Large Cell Lymphoma With Positive ALK Expression and a Rapidly Progressive Cutaneous Nodule. Int J Surg Pathol 2015;23:333-5. [DOI: 10.1177/1066896915568993] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
43 Bertolotti A, Pham-ledard A, Vergier B, Parrens M, Bedane C, Beylot-barry M. Lymphomatoid papulosis type D: an aggressive histology for an indolent disease. Br J Dermatol 2013;169:1157-9. [DOI: 10.1111/bjd.12463] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
44 Lai P, Wang Y. Epigenetics of cutaneous T-cell lymphoma: biomarkers and therapeutic potentials. Cancer Biol Med 2021;18:34-51. [PMID: 33628583 DOI: 10.20892/j.issn.2095-3941.2020.0216] [Reference Citation Analysis]
45 Sandoval J, Díaz-lagares A, Salgado R, Servitje O, Climent F, Ortiz-romero PL, Pérez-ferriols A, Garcia-muret MP, Estrach T, Garcia M, Nonell L, Esteller M, Pujol RM, Espinet B, Gallardo F. MicroRNA Expression Profiling and DNA Methylation Signature for Deregulated MicroRNA in Cutaneous T-Cell Lymphoma. Journal of Investigative Dermatology 2015;135:1128-37. [DOI: 10.1038/jid.2014.487] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 8.1] [Reference Citation Analysis]
46 Jepsen ME, Gniadecki R. Treatment of primary cutaneous anaplastic large cell lymphoma with superficial x-rays. Dermatol Reports 2015;7:5888. [PMID: 25918620 DOI: 10.4081/dr.2015.5888] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
47 Reddy V, Thibodeaux Q, Bhutani T, Sugarman JL. Lymphomatoid papulosis successfully managed with excimer laser maintenance therapy. JAAD Case Rep 2020;6:495-7. [PMID: 32490107 DOI: 10.1016/j.jdcr.2020.04.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Stranzenbach R, Stadler R. Combination of brentuximab-vedotin with skin-directed therapies extends the time to the next therapeutic line in patients with cutaneous T-cell lymphoma. J Dtsch Dermatol Ges 2021;19:383-7. [PMID: 33617153 DOI: 10.1111/ddg.14342] [Reference Citation Analysis]
49 Cañueto J, Ocio EM, Román-Curto C. Aggressive primary cutaneous CD30+ lymphoproliferative disorder in an organ transplant recipient in sustained complete remission with brentuximab vedotin. Int J Dermatol 2018;57:e153-5. [PMID: 30191555 DOI: 10.1111/ijd.14214] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
50 Fleming D, Stone J, Tansley P. Spontaneous Regression and Resolution of Breast Implant-Associated Anaplastic Large Cell Lymphoma: Implications for Research, Diagnosis and Clinical Management. Aesthetic Plast Surg 2020;44:1109-15. [PMID: 32766915 DOI: 10.1007/s00266-020-01810-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Lewis DJ, Talpur R, Huen AO, Tetzlaff MT, Duvic M. Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results. JAMA Dermatol 2017;153:1302-6. [PMID: 28980004 DOI: 10.1001/jamadermatol.2017.3593] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
52 Sauder MB, O'Malley JT, LeBoeuf NR. CD30+ Lymphoproliferative Disorders of the Skin. Hematol Oncol Clin North Am 2017;31:317-34. [PMID: 28340881 DOI: 10.1016/j.hoc.2016.11.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
53 Ferranti M, Salmaso R, Marino D, Alaibac M. A rare case of early-onset lymphomatoid papulosis refractory to brentuximab vedotin. Dermatol Ther 2021;34:e14943. [PMID: 33719147 DOI: 10.1111/dth.14943] [Reference Citation Analysis]
54 Fleming D, Stone J, Tansley P. Spontaneous Regression and Resolution of Breast Implant-Associated Anaplastic Large Cell Lymphoma: Implications for Research, Diagnosis and Clinical Management. Aesthetic Plast Surg 2018;42:672-8. [PMID: 29445921 DOI: 10.1007/s00266-017-1064-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
55 Fernández-de-Misa R, Hernández-Machín B, Combalía A, García Muret MP, Servitje O, Muniesa C, Gallardo F, Pujol RM, Martí RM, Ortiz-Brugués A, Maroñas-Jiménez L, Ortiz-Romero PL, Blanch Rius L, Izu R, Román C, Cañueto J, Blanes M, Morillo M, Bastida J, Peñate Y, Pérez Gala S, Espinosa Lara P, Pérez Gil A, Estrach T. Prognostic factors in patients with primary cutaneous anaplastic large cell lymphoma: a multicentric, retrospective analysis of the Spanish Group of Cutaneous Lymphoma. J Eur Acad Dermatol Venereol 2020;34:762-8. [PMID: 31591786 DOI: 10.1111/jdv.16006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
56 Di Raimondo C, Parekh V, Song JY, Rosen ST, Querfeld C, Zain J, Martinez XU, Abdulla FR. Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review. Curr Hematol Malig Rep 2020;15:333-42. [DOI: 10.1007/s11899-020-00583-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
57 Rodríguez-Pinilla SM, Ortiz-Romero PL, Monsalvez V, Tomás IE, Almagro M, Sevilla A, Camacho G, Longo MI, Pulpillo Á, Diaz-Pérez JA. TCR-γ expression in primary cutaneous T-cell lymphomas. Am J Surg Pathol. 2013;37:375-384. [PMID: 23348211 DOI: 10.1097/pas.0b013e318275d1a2] [Cited by in Crossref: 90] [Cited by in F6Publishing: 24] [Article Influence: 10.0] [Reference Citation Analysis]
58 Wohlmuth-Wieser I. Primary cutaneous T-cell lymphomas in childhood and adolescence. J Dtsch Dermatol Ges 2021;19:563-81. [PMID: 33861015 DOI: 10.1111/ddg.14509] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 van de Donk NW, Dhimolea E. Brentuximab vedotin. MAbs. 2012;4:458-465. [PMID: 22684302 DOI: 10.4161/mabs.20230] [Cited by in Crossref: 69] [Cited by in F6Publishing: 57] [Article Influence: 6.9] [Reference Citation Analysis]
60 Tandberg DJ, Craciunescu O, Kelsey CR. Radiation Therapy for Cutaneous T-Cell Lymphomas. Dermatol Clin 2015;33:703-13. [PMID: 26433843 DOI: 10.1016/j.det.2015.05.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
61 Quintanilla-Martinez L, Jansen PM, Kinney MC, Swerdlow SH, Willemze R. Non-mycosis fungoides cutaneous T-cell lymphomas: report of the 2011 Society for Hematopathology/European Association for Haematopathology workshop. Am J Clin Pathol. 2013;139:491-514. [PMID: 23525618 DOI: 10.1309/ajcp83aoqtmlojtm] [Cited by in Crossref: 50] [Cited by in F6Publishing: 9] [Article Influence: 5.6] [Reference Citation Analysis]
62 Wang Y, Bagot M. Updates in cutaneous lymphoma: evidence-based guidelines for the management of cutaneous lymphoma 2018. Br J Dermatol 2019;180:443-4. [PMID: 30821385 DOI: 10.1111/bjd.17523] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
63 Goodlad JR. The many faces of lymphomatoid papulosis. Diagnostic Histopathology 2014;20:263-70. [DOI: 10.1016/j.mpdhp.2014.05.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
64 Melchers RC, Willemze R, Daniëls LA, Neelis KJ, Bekkenk MW, de Haas ER, Horvath B, van Rossum MM, Sanders CJ, Velstra B, Veraart JC, Roach RE, Vermeer MH, Quint KD. Recommendations for the Optimal Radiation Dose in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma: A Report of the Dutch Cutaneous Lymphoma Group. International Journal of Radiation Oncology*Biology*Physics 2017;99:1279-85. [DOI: 10.1016/j.ijrobp.2017.08.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
65 Hughey LC. Practical Management of CD30⁺ Lymphoproliferative Disorders. Dermatol Clin 2015;33:819-33. [PMID: 26433852 DOI: 10.1016/j.det.2015.05.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
66 Melchers RC, Willemze R, Bekkenk MW, de Haas ERM, Horvath B, van Rossum MM, Sanders CJG, Veraart JCJM, Putter H, Jansen PM, Vermeer MH, Quint KD. Frequency and prognosis of associated malignancies in 504 patients with lymphomatoid papulosis. J Eur Acad Dermatol Venereol 2020;34:260-6. [PMID: 31715046 DOI: 10.1111/jdv.16065] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
67 Mira-Perceval Juan G, Alcalá Minagorre PJ, Huertas Sánchez AM, Segura Sánchez S, López Iniesta S, De León Marrero FJ, Costa Navarro E, Niveiro de Jaime M. Cardiac Tamponade Associated with the Presentation of Anaplastic Large Cell Lymphoma in a 2-Year-Old Child. Case Rep Pediatr 2015;2015:487491. [PMID: 26435869 DOI: 10.1155/2015/487491] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
68 Merlio JP, Kadin ME. Cytokines, Genetic Lesions and Signaling Pathways in Anaplastic Large Cell Lymphomas. Cancers (Basel) 2021;13:4256. [PMID: 34503066 DOI: 10.3390/cancers13174256] [Reference Citation Analysis]
69 Bilgiç Temel A, Unal B, Erdi Şanlı H, Duygulu Ş, Uzun S. A Severe Case of Lymphomatoid Papulosis Type E Successfully Treated with Interferon-Alfa 2a. Case Rep Dermatol Med 2017;2017:3194738. [PMID: 28540091 DOI: 10.1155/2017/3194738] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
70 de Graauw E, Beltraminelli H, Simon HU, Simon D. Eosinophilia in Dermatologic Disorders. Immunol Allergy Clin North Am 2015;35:545-60. [PMID: 26209899 DOI: 10.1016/j.iac.2015.05.005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
71 Desai A, Telang GH, Olszewski AJ. Remission of primary cutaneous anaplastic large cell lymphoma after a brief course of brentuximab vedotin. Ann Hematol 2013;92:567-8. [PMID: 23086510 DOI: 10.1007/s00277-012-1610-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
72 Borghi A, Caselli E, Di Luca D, Sebastiani A, Perri P, Seraceni S, Contini C, Virgili A. Detection of Chlamydophila pneumoniae and human herpesvirus 8 in primary cutaneous anaplastic large-cell lymphoma: a case report. Infect Agent Cancer 2013;8:41. [PMID: 24099147 DOI: 10.1186/1750-9378-8-41] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
73 Pedretti S, Urpis M, Leali C, Borghetti P, Baushi L, Sala R, Tucci A, Greco D, Pasinetti N, Triggiani L, Rossi G, Calzavara-Pinton P, Magrini SM, Buglione M. Primary cutaneous non-Hodgkin lymphoma: results of a retrospective analysis in the light of the recent ILROG guidelines. Tumori 2018;104:394-400. [PMID: 28218382 DOI: 10.5301/tj.5000606] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
74 Wang Y, Gu X, Zhang G, Wang L, Wang T, Zhao Y, Zhang X, Zhou Y, Kadin M, Tu P. SATB1 overexpression promotes malignant T-cell proliferation in cutaneous CD30+ lymphoproliferative disease by repressing p21. Blood 2014;123:3452-61. [PMID: 24747435 DOI: 10.1182/blood-2013-10-534693] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
75 Shinohara MM, Shustov A. How I treat primary cutaneous CD30+ lymphoproliferative disorders. Blood 2019;134:515-24. [DOI: 10.1182/blood.2019000785] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
76 Zhou A, Damsky W, Girardi M, Foss FM, Vesely MD. Necrotic papulonodules on the legs. JAAD Case Rep 2021;11:10-2. [PMID: 33898676 DOI: 10.1016/j.jdcr.2021.03.012] [Reference Citation Analysis]
77 Ohtsuka M, Hamada T, Miyagaki T, Shimauchi T, Yonekura K, Kiyohara E, Fujita H, Izutsu K, Okuma K, Kawai K, Koga H, Sugaya M. Outlines of the Japanese guidelines for the management of primary cutaneous lymphomas 2020. J Dermatol 2021;48:e49-71. [PMID: 33245165 DOI: 10.1111/1346-8138.15707] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
78 Bennani-Baiti N, Ansell S, Feldman AL. Adult systemic anaplastic large-cell lymphoma: recommendations for diagnosis and management. Expert Rev Hematol. 2016;9:137-150. [PMID: 26581318 DOI: 10.1586/17474086.2016.1122514] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
79 Sasapu A, Dunn ALJ, Gardner J, Wong HK. Remission of refractory granulomatous primary cutaneous anaplastic large cell lymphoma to brentuximab vedotin. BMJ Case Rep 2021;14:e242896. [PMID: 34290015 DOI: 10.1136/bcr-2021-242896] [Reference Citation Analysis]
80 Parajuli S, Gurung D, Paudel U, Pokhrel DB, Kempf W. Primary cutaneous CD30-positive anaplastic large cell lymphoma in an 80-year-old man: a case report from Nepal. Int J Dermatol 2014;53:1498-500. [PMID: 24738699 DOI: 10.1111/j.1365-4632.2012.05802.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
81 Wieser I, Oh CW, Talpur R, Duvic M. Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients. Journal of the American Academy of Dermatology 2016;74:59-67. [DOI: 10.1016/j.jaad.2015.09.013] [Cited by in Crossref: 68] [Cited by in F6Publishing: 53] [Article Influence: 11.3] [Reference Citation Analysis]
82 Lorio M, Lewis B, Hoy J, Yeager M. AGENT ORANGE-INDUCED Anaplastic Large-Cell Lymphoma (ALCL) with Cutaneous Involvement. Clin Case Rep 2021;9:2373-81. [PMID: 33936698 DOI: 10.1002/ccr3.4041] [Reference Citation Analysis]
83 López-Sánchez C, Iznardo H, Mozos A, Flores-Climente V, Puig L. Purple ulcerated nodules in a middle-aged man. Int J Dermatol 2020;59:e96-8. [PMID: 31930730 DOI: 10.1111/ijd.14771] [Reference Citation Analysis]
84 Sica A, Vitiello P, Ronchi A, Casale B, Calogero A, Sagnelli E, Costa Nachtigal G, Troiani T, Franco R, Argenziano G, Moscarella E, Sagnelli C. Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) in the Elderly and the Importance of Sport Activity Training. Int J Environ Res Public Health 2020;17:E839. [PMID: 32013101 DOI: 10.3390/ijerph17030839] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
85 Natsuaki Y, Muto I, Kawamura M, Saruta H, Teye K, Ohshima K, Nakama T, Ohata C. Sarcomatoid Variant of Primary Cutaneous Anaplastic Large Cell Lymphoma. The American Journal of Dermatopathology 2019;41:e164-7. [DOI: 10.1097/dad.0000000000001483] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
86 Arroyo-Andrés J, Agud-Dios M, Rubio-Muniz CA, Vico-Alonso C, Cortijo-Cascajares S, Ortiz-Romero PL. Primary cutaneous anaplastic large-cell lymphoma successfully treated with intralesional brentuximab vedotin: a case report. Int J Dermatol 2021. [PMID: 34363613 DOI: 10.1111/ijd.15834] [Reference Citation Analysis]
87 Oschlies I, Lisfeld J, Lamant L, Nakazawa A, d'Amore ES, Hansson U, Hebeda K, Simonitsch-Klupp I, Maldyk J, Müllauer L, Tinguely M, Stücker M, Ledeley MC, Siebert R, Reiter A, Brugières L, Klapper W, Woessmann W. ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study. Haematologica 2013;98:50-6. [PMID: 22773605 DOI: 10.3324/haematol.2012.065664] [Cited by in Crossref: 80] [Cited by in F6Publishing: 61] [Article Influence: 8.0] [Reference Citation Analysis]
88 Kempf W, Zimmermann AK, Mitteldorf C. Cutaneous lymphomas-An update 2019. Hematol Oncol 2019;37 Suppl 1:43-7. [PMID: 31187534 DOI: 10.1002/hon.2584] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
89 Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M; ESMO Guidelines Committee. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29:iv30-40. [PMID: 29878045 DOI: 10.1093/annonc/mdy133] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 22.3] [Reference Citation Analysis]
90 van Anrooij B, Kluin PM, Oude Elberink JN, Kluin-Nelemans JC. CD30 in systemic mastocytosis. Immunol Allergy Clin North Am 2014;34:341-55. [PMID: 24745678 DOI: 10.1016/j.iac.2014.01.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
91 Whittaker S, Knobler R, Ortiz P, Vermeer M, Karrasch M, Hasan B, Lacombe D, Kempf W, Dummer R, Bagot M. Major achievements of the EORTC Cutaneous Lymphoma Task Force (CLTF). European Journal of Cancer Supplements 2012;10:46-50. [DOI: 10.1016/s1359-6349(12)70010-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
92 Quaglino P, Fava P, Pileri A, Grandi V, Sanlorenzo M, Panasiti V, Guglielmo A, Alberti-Violetti S, Novelli M, Astrua C, Rubatto M, Tonella L, Berti E, Pimpinelli N, Osella Abate S, Fierro MT, Vermeer M, Scarisbrick JJ, Ribero S. Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or Sézary Syndrome. J Invest Dermatol 2021;141:484-95. [PMID: 33162051 DOI: 10.1016/j.jid.2020.07.026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
93 Hamdi M. Association Between Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Risk and Polyurethane Breast Implants: Clinical Evidence and European Perspective. Aesthetic Surgery Journal 2019;39:S49-54. [DOI: 10.1093/asj/sjy328] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
94 Kempf W, Mitteldorf C, Karai LJ, Robson A. Die histologischen Typen der lymphomatoiden Papulose - Ein Vorschlag für die Vereinfachung des Buchstabenchaos: Terminologie der lymphomatoiden Papulose. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2017;15:390-4. [DOI: 10.1111/ddg.13207_g] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
95 Garcias-ladaria J, Fink-puches R, Wolf I, Cerroni L. Acral Lymphomatoid Papulosis With Hemorrhagic Features Mimicking a Vasculitis: . Pathology Case Reviews 2014;19:191-4. [DOI: 10.1097/pcr.0000000000000048] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
96 Oliveira LS, Nobrega MP, Monteiro MG, Almeida WL. Primary cutaneous anaplastic large-cell lymphoma--case report. An Bras Dermatol 2013;88:132-5. [PMID: 24346900 DOI: 10.1590/abd1806-4841.20131731] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
97 Kavvalou E, Stefanidou M, Krueger-Krasagakis SE, Evangelou G, Koumaki D, Marinos L, Tzardi M, Krasagakis K. Lymphomatoid Papulosis Type A: A Case Report of the "Wait-and-See Strategy" in a 27-Year-Old Male Patient with Extensive Disease. Case Rep Dermatol Med 2019;2019:1765210. [PMID: 31380123 DOI: 10.1155/2019/1765210] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
98 Scarisbrick JJ, Bagot M, Ortiz-Romero PL. The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell lymphoma. Br J Haematol 2021;192:683-96. [PMID: 33095448 DOI: 10.1111/bjh.17117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
99 Nguyen CN, Iyer SP, Miranda RN, Torres-Cabala CA, Curry JL, Fang P, Thomas VD, Huen AO. Aggressive primary cutaneous anaplastic large cell lymphoma with massive bilateral upper limb involvement at relapse. JAAD Case Rep 2021;17:34-7. [PMID: 34692965 DOI: 10.1016/j.jdcr.2021.09.005] [Reference Citation Analysis]
100 Wagner G, Rose C, Klapper W, Sachse MM. Lymphomatoid papulosis. J Dtsch Dermatol Ges 2020;18:199-205. [PMID: 32100965 DOI: 10.1111/ddg.14041] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
101 Willemze R, Hodak E, Zinzani P, Specht L, Ladetto M. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2013;24:vi149-54. [DOI: 10.1093/annonc/mdt242] [Cited by in Crossref: 89] [Cited by in F6Publishing: 74] [Article Influence: 9.9] [Reference Citation Analysis]
102 Battistella M, Janin A, Jean-louis F, Collomb C, Leboeuf C, Sicard H, Bonnafous C, Dujardin A, Ram-wolff C, Kadin M, Bensussan A, Bagot M, Michel L. KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma. Br J Dermatol 2016;175:325-33. [DOI: 10.1111/bjd.14626] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
103 Sherry AD, Ding GX, Kirschner AN. Diffuse Primary Cutaneous Anaplastic Large Cell Lymphoma Treated by Rotational Total Skin Electron Beam Radiotherapy with Custom Shielding: Case Report. J Med Imaging Radiat Sci 2019;50:454-9. [PMID: 31213358 DOI: 10.1016/j.jmir.2019.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
104 Kempf W, Kazakov DV, Belousova IE, Mitteldorf C, Kerl K. Paediatric cutaneous lymphomas: a review and comparison with adult counterparts. J Eur Acad Dermatol Venereol 2015;29:1696-709. [PMID: 25715748 DOI: 10.1111/jdv.13044] [Cited by in Crossref: 38] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
105 Nikolaou V, Papadavid E, Ekonomidi A, Dalamaga M, Marinos L, Stratigos A, Papadaki T, Antoniou C. Association of clinicopathological characteristics with secondary neoplastic lymphoproliferative disorders in patients with lymphomatoid papulosis. Leuk Lymphoma 2015;56:1303-7. [PMID: 25242096 DOI: 10.3109/10428194.2014.958821] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
106 Wobser M, Roth S, Appenzeller S, Kneitz H, Goebeler M, Geissinger E, Rosenwald A, Maurus K. Oncogenic Mutations and Gene Fusions in CD30-Positive Lymphoproliferations and Clonally Related Mycosis Fungoides Occurring in the Same Patients. JID Innov 2021;1:100034. [PMID: 34909731 DOI: 10.1016/j.xjidi.2021.100034] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Chen X, Soma LA, Fromm JR. Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin. Onco Targets Ther 2013;7:45-56. [PMID: 24379682 DOI: 10.2147/OTT.S39107] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
108 Willemze R, Hodak E, Zinzani P, Specht L, Ladetto M. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2018;29:iv30-40. [DOI: 10.1093/annonc/mdy133] [Reference Citation Analysis]
109 Lebel E, Benshushan S, Paltiel O. From the Skin Straight to the Brain: Rare CNS Recurrence of Cutaneous Anaplastic Large Cell Lymphoma. JCO Oncol Pract 2020;16:247-8. [PMID: 32240069 DOI: 10.1200/JOP.19.00581] [Reference Citation Analysis]
110 Dereure O. [Primary skin lymphomas: Current therapy]. Ann Dermatol Venereol 2019;146:92-9. [PMID: 30709635 DOI: 10.1016/j.annder.2018.11.012] [Reference Citation Analysis]
111 Eder J, Kern A, Moser J, Kitzwögerer M, Sedivy R, Trautinger F. Frequency of primary cutaneous lymphoma variants in Austria: retrospective data from a dermatology referral centre between 2006 and 2013. J Eur Acad Dermatol Venereol 2015;29:1517-23. [PMID: 25600184 DOI: 10.1111/jdv.12907] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
112 Million L, Yi EJ, Wu F, Von Eyben R, Campbell BA, Dabaja B, Tsang RW, Ng A, Wilson LD, Ricardi U, Kirova Y, Hoppe RT. Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: An International Lymphoma Radiation Oncology Group Multi-institutional Experience. Int J Radiat Oncol Biol Phys 2016;95:1454-9. [PMID: 27315663 DOI: 10.1016/j.ijrobp.2016.03.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
113 Baykal C, Kılıç Sayar S, Yazganoğlu KD, Büyükbabani N. Evaluation of Associated Lymphomas and Their Risk Factors in Patients with Lymphomatoid Papulosis: A Retrospective Single-Center Study from Turkey. Turk J Haematol 2021;38:49-56. [PMID: 33389922 DOI: 10.4274/tjh.galenos.2020.2020.0685] [Reference Citation Analysis]
114 Adamski H, Ingen‐housz‐oro S, Machet L, Carriou A, Ram‐wolff C, Ortonne N, Le Gall F, Durlach A, Dupuis J, Dauriac C, Dupuy A, Grange F, Bagot M. Lymphomatoid papulosis associated with chronic lymphocytic leukaemia/small lymphocytic lymphoma: three cases. Br J Dermatol 2018;178. [DOI: 10.1111/bjd.15698] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
115 Xiong J, Ma Y, Chen H, Xu X, Sun J. Lymphomatoid papulosis with pseudocarcinomatous hyperplasia in a 7-year-old girl: a case report: A special presentation of LyP. J Cutan Pathol 2016;43:430-3. [DOI: 10.1111/cup.12646] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
116 Piccinno R, Damiani G, Rossi LC, Berti E. Radiotherapy of primary cutaneous anaplastic large cell lymphoma: our experience in 30 cases. Int J Dermatol 2020;59:469-73. [PMID: 31916593 DOI: 10.1111/ijd.14754] [Reference Citation Analysis]
117 Saggini A, Anemona L, Chimenti S, Sarmati L, Torti C, Di Stefani A, Bianchi L. HIV-associated primary cutaneous anaplastic large cell lymphoma: a clinicopathological subset with more aggressive behavior? Case report and review of the literature: HIV-associated primary cutaneous ALCL. J Cutan Pathol 2012;39:1100-9. [DOI: 10.1111/cup.12020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
118 Kempf W. A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders. Semin Diagn Pathol 2017;34:22-35. [PMID: 27993440 DOI: 10.1053/j.semdp.2016.11.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
119 Story SK, Schowalter MK, Geskin LJ. Breast implant-associated ALCL: a unique entity in the spectrum of CD30+ lymphoproliferative disorders. Oncologist 2013;18:301-7. [PMID: 23429741 DOI: 10.1634/theoncologist.2012-0238] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 5.0] [Reference Citation Analysis]
120 Kempf W, Mitteldorf C. Cutaneous T-cell lymphomas-An update 2021. Hematol Oncol 2021;39 Suppl 1:46-51. [PMID: 34105822 DOI: 10.1002/hon.2850] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
121 Kempf W, Keller K, John H, Dommann-scherrer C. Benign Atypical Intravascular CD30+ T-Cell Proliferation: A Recently Described Reactive Lymphoproliferative Process and Simulator of Intravascular Lymphoma. American Journal of Clinical Pathology 2014;142:694-9. [DOI: 10.1309/ajcpxoe61cjdoaji] [Cited by in Crossref: 23] [Cited by in F6Publishing: 2] [Article Influence: 2.9] [Reference Citation Analysis]
122 Chen C, Gu YD, Geskin LJ. A Review of Primary Cutaneous CD30+ Lymphoproliferative Disorders. Hematology/Oncology Clinics of North America 2019;33:121-34. [DOI: 10.1016/j.hoc.2018.08.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
123 Fernández-de-misa R, Hernández-machín B, Servitje O, Valentí-medina F, Maroñas-jiménez L, Ortiz-romero PL, Sánchez Schmidt J, Pujol RM, Gallardo F, Pau-charles I, García Muret MP, Pérez Gala S, Román C, Cañueto J, Blanch Rius L, Izu R, Ortiz-brugués A, Martí RM, Blanes M, Morillo M, Sánchez P, Peñate Y, Bastida J, Pérez Gil A, Lopez-lerma I, Muniesa C, Estrach T. First-line treatment in lymphomatoid papulosis: a retrospective multicentre study. Clin Exp Dermatol 2018;43:137-43. [DOI: 10.1111/ced.13256] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
124 Pujol R, Gallardo F. Linfomas cutáneos. Parte I: micosis fungoide, síndrome de Sézary y proliferaciones linfoides cutáneas CD30 positivas. Actas Dermo-Sifiliográficas 2021;112:14-23. [DOI: 10.1016/j.ad.2020.08.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Maurus K, Appenzeller S, Roth S, Brändlein S, Kneitz H, Goebeler M, Rosenwald A, Geissinger E, Wobser M. Recurrent Oncogenic JAK and STAT Alterations in Cutaneous CD30-Positive Lymphoproliferative Disorders. J Invest Dermatol 2020;140:2023-2031.e1. [PMID: 32147503 DOI: 10.1016/j.jid.2020.02.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Miquel J, Fraitag S, Hamel‐teillac D, Molina T, Brousse N, Prost Y, Bodemer C. Lymphomatoid papulosis in children: a series of 25 cases. Br J Dermatol 2014;171:1138-46. [DOI: 10.1111/bjd.13061] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
127 Kempf W, Kazakov DV, Schärer L, Rütten A, Mentzel T, Paredes BE, Palmedo G, Panizzon RG, Kutzner H. Angioinvasive Lymphomatoid Papulosis: A New Variant Simulating Aggressive Lymphomas. American Journal of Surgical Pathology 2013;37:1-13. [DOI: 10.1097/pas.0b013e3182648596] [Cited by in Crossref: 130] [Cited by in F6Publishing: 15] [Article Influence: 14.4] [Reference Citation Analysis]
128 Rubio-Gonzalez B, Zain J, Rosen ST, Querfeld C. Clinical manifestations and pathogenesis of cutaneous lymphomas: current status and future directions. Br J Haematol 2017;176:16-36. [PMID: 27782301 DOI: 10.1111/bjh.14402] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
129 Milan E, Miceli P, Sernicola A, Finotto S, Marino D, Alaibac M. Complete remission of primary cutaneous anaplastic large cell lymphoma after a short course of brentuximab vedotin. Mol Clin Oncol 2021;14:121. [PMID: 33936594 DOI: 10.3892/mco.2021.2283] [Reference Citation Analysis]
130 Wood GS, Wu J. Methotrexate and Pralatrexate. Dermatol Clin 2015;33:747-55. [PMID: 26433846 DOI: 10.1016/j.det.2015.05.009] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
131 Word AP, Cayce R, Pandya AG. Beware of Underlying Malignancy: Acquired Ichthyosis. The American Journal of Medicine 2014;127:202-4. [DOI: 10.1016/j.amjmed.2013.12.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
132 Prieto-Torres L, Rodriguez-Pinilla SM, Onaindia A, Ara M, Requena L, Piris MÁ. CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies. Haematologica 2019;104:226-35. [PMID: 30630983 DOI: 10.3324/haematol.2018.197152] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
133 Ceppi F, Pope E, Ngan B, Abla O. Primary Cutaneous Lymphomas in Children and Adolescents: Cutaneous Lymphomas in Children and Adolescents. Pediatr Blood Cancer 2016;63:1886-94. [DOI: 10.1002/pbc.26076] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
134 Nambudiri VE, Aboutalebi A, Granter SR, Saavedra A. Recurrent ALK-Negative Anaplastic Large T-Cell Lymphoma Presenting as Necrotizing Vasculitis. The American Journal of Dermatopathology 2013;35:512-6. [DOI: 10.1097/dad.0b013e31827a0cda] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
135 Fauconneau A, Pham-ledard A, Cappellen D, Frison E, Prochazkova-carlotti M, Parrens M, Dalle S, Joly P, Viraben R, Franck F, Ingen-housz-oro S, Giacchero D, Jullié M, Vergier B, Merlio J, Beylot-barry M. Assessment of diagnostic criteria between primary cutaneous anaplastic large-cell lymphoma and CD30-rich transformed mycosis fungoides; a study of 66 cases. Br J Dermatol 2015;172:1547-54. [DOI: 10.1111/bjd.13690] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
136 Gratzinger D, Million L, Kim YH. Occult Dermal Lymphatic Involvement Is Frequent in Primary Cutaneous Anaplastic Large Cell Lymphoma. Am J Dermatopathol 2015;37:767-70. [PMID: 26381026 DOI: 10.1097/DAD.0000000000000377] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
137 Romano RC, Cohen DN, Howard MT, Wieland CN. A Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorder Arising in a Patient With Multiple Myeloma and Cutaneous Amyloidosis. Am J Dermatopathol 2016;38:388-92. [PMID: 26981738 DOI: 10.1097/DAD.0000000000000534] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
138 Turrión-Merino L, Perez-Gala S, Hermosa-Zarza E, Urech-García-de-la-Vega M, Carrillo-Guijón R, Jaén-Olasolo P. Primary cutaneous CD30+ anaplastic large cell lymphoma treated with radiotherapy and methotrexate with development of xanthomas at the sites of prior disease. J Cutan Pathol 2016;43:400-5. [PMID: 26695345 DOI: 10.1111/cup.12661] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
139 Su C, Nguyen KA, Bai HX, Zogg CK, Cao Y, Karakousis G, Zhang PJ, Zhang G, Xiao R. Ethnic disparity in primary cutaneous CD30+ T-cell lymphoproliferative disorders: an analysis of 1496 cases from the US National Cancer Database. Br J Haematol 2018;181:752-9. [PMID: 29676444 DOI: 10.1111/bjh.15222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
140 Caselli E, Borghi A, Maritati M, Gafà R, Lanza G, Di Luca D, Virgili A, Contini C. Relapses of primary cutaneous anaplastic large-cell lymphoma in a female immunocompetent patient with persistent chlamydophila pneumoniae and human herpesvirus 8 infection. Infect Agent Cancer 2016;11:31. [PMID: 27382410 DOI: 10.1186/s13027-016-0079-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
141 Geller S, Canavan TN, Pulitzer M, Moskowitz AJ, Myskowski PL. ALK-positive primary cutaneous anaplastic large cell lymphoma: a case report and review of the literature. Int J Dermatol 2018;57:515-20. [PMID: 29057463 DOI: 10.1111/ijd.13804] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
142 Kempf W. Multifocal anaplastic large cell lymphoma - insight into its biology and treatment. Br J Dermatol 2018;179:565-6. [PMID: 30222874 DOI: 10.1111/bjd.16814] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
143 Dummer R, Prince HM, Whittaker S, Horwitz SM, Kim YH, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Eradat H, Pinter-Brown L, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Huen A, Walewski J, Wang Y, Lisano J, Richhariya A, Feliciano J, Zhu Y, Bunn V, Little M, Zagadailov E, Dalal MR, Duvic M. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. Eur J Cancer 2020;133:120-30. [PMID: 32502876 DOI: 10.1016/j.ejca.2020.04.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
144 Gilson D, Whittaker S, Child F, Scarisbrick J, Illidge T, Parry E, Mohd Mustapa M, Exton L, Kanfer E, Rezvani K, Dearden C, Morris S, Mchenry P, Leslie T, Wakelin S, Hunasehally R, Cork M, Johnston G, Chiang N, Worsnop F, Salim A, Buckley D, Petrof G, Callachand N, Flavell T, Salad A. British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. Br J Dermatol 2019;180:496-526. [DOI: 10.1111/bjd.17240] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 11.8] [Reference Citation Analysis]
145 Taskinen M, Jeskanen L, Karjalainen-Lindsberg ML, Mäkitie A, Mäkitie O, Ranki A. Combating cancer predisposition in association with idiopathic immune deficiency: a recurrent nodal and cutaneous T-cell lymphoproliferative disease in a patient with cartilage-hair hypoplasia. Clin Lymphoma Myeloma Leuk 2013;13:73-6. [PMID: 22999941 DOI: 10.1016/j.clml.2012.06.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
146 Mitteldorf C, Grabbe S, Stadler R. WHO-Klassifikation und klinisches Spektrum der kutanen Lymphome. Hautarzt 2017;68:682-95. [DOI: 10.1007/s00105-017-4025-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
147 Wasik MA, Jimenez GS, Weisenburger DD. Targeting CD30 in malignant tissues: challenges in detection and clinical applications. Pathobiology 2013;80:252-8. [PMID: 23689361 DOI: 10.1159/000347192] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
148 Vaklavas C, Forero-Torres A. Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Ther Adv Hematol 2012;3:209-25. [PMID: 23606932 DOI: 10.1177/2040620712443076] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
149 AbuHilal M, Walsh S, Shear N. Associated Hematolymphoid Malignancies in Patients With Lymphomatoid Papulosis: A Canadian Retrospective Study. J Cutan Med Surg 2017;21:507-12. [PMID: 28614957 DOI: 10.1177/1203475417716366] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
150 Haus G, Utikal J, Geraud C, Goerdt S, Leverkus M. CD 30‐positive lymphoproliferative disorder in a red tattoo: regional lymphomatoid papulosis type C or pseudolymphoma? Br J Dermatol 2014;171:668-70. [DOI: 10.1111/bjd.13024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
151 Olsen EA. Evaluation, Diagnosis, and Staging of Cutaneous Lymphoma. Dermatol Clin 2015;33:643-54. [PMID: 26433839 DOI: 10.1016/j.det.2015.06.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
152 Hapgood G, Pickles T, Sehn LH, Villa D, Klasa R, Scott DW, Gerrie AS, Gascoyne RD, Slack GW, Parsons C, Morris JW, Connors JM, Savage KJ. Outcome of primary cutaneous anaplastic large cell lymphoma: a 20-year British Columbia Cancer Agency experience. Br J Haematol 2017;176:234-40. [DOI: 10.1111/bjh.14404] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
153 Wieser I, Wohlmuth C, Nunez CA, Duvic M. Lymphomatoid Papulosis in Children and Adolescents: A Systematic Review. Am J Clin Dermatol 2016;17:319-27. [DOI: 10.1007/s40257-016-0192-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
154 Lange HJ, Agertoft L, Møller MB, Clemmensen O, Kristensen T, Vestergaard H, Mørtz CG, Bindslev-Jensen C, Broesby-Olsen S; Mastocytosis Centre Odense University Hospital (MastOUH). A child with mastocytosis and lymphomatoid papulosis. Clin Case Rep 2016;4:517-9. [PMID: 27190619 DOI: 10.1002/ccr3.551] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
155 Thompson PA, Prince HM. Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Systematic Review of the Literature and Mini-Meta Analysis. Curr Hematol Malig Rep 2013;8:196-210. [DOI: 10.1007/s11899-013-0164-3] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 5.8] [Reference Citation Analysis]
156 Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin H, Liu Y, Huebner D, Little M, Whittaker S, Duvic M, Trotman J, Joske D, Prince HM, Taylor K, Lewis ID, Jonak C, Trautinger F, Bechter O, Wolter P, Bron D, de Lima VCC, Sanches JA, Klasa R, Bagot M, Beylot-barry M, Dalle S, D'incan M, Dreno B, Grange F, Nicolay J, Stadler R, Weichenthal M, Wobser M, Assaf C, Loquai C, Quaglino P, Spina M, Zinzani PL, Bosi A, Fattori PP, Grzanka A, Walewski J, Lopez-hernandez A, Ortiz-romero PL, Roca JJR, Canales SN, Dummer R, Illidge T, Johnson R, Whittaker S, Morris S, Mckay P, Scarisbrick J, Duvic M, Feldman T, Akilov O, Geskin L, Horwitz S, Kim YH, Pro B, Kuzel T, Lerner A, Eradat H, Sokol L, Fisher DC, Hughey S. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. The Lancet 2017;390:555-66. [DOI: 10.1016/s0140-6736(17)31266-7] [Cited by in Crossref: 268] [Cited by in F6Publishing: 98] [Article Influence: 53.6] [Reference Citation Analysis]
157 Cordel N, Tressières B, D'Incan M, Machet L, Grange F, Estève É, Dalac S, Ingen-Housz-Oro S, Bagot M, Beylot-Barry M, Joly P; French Study Group on Cutaneous Lymphoma. Frequency and Risk Factors for Associated Lymphomas in Patients With Lymphomatoid Papulosis. Oncologist 2016;21:76-83. [PMID: 26668250 DOI: 10.1634/theoncologist.2015-0242] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 3.9] [Reference Citation Analysis]
158 Bergqvist C, Beylot-Barry M, Ram-Wolff C, Vergier B, Bagot M, Battistella M, Dalle S, Balme B, Merlio JP, Durupt F, Le Corre Y, Bonnet N, Le Bozec P, Skowron F, Vivard-Wallee I, Dereure O, Brunet-Possenti F, Ingen-Housz-Oro S, Ortonne N. Lymphomatoid papulosis types D and E: a multicentre series of the French Cutaneous Lymphomas Study Group. Clin Exp Dermatol 2021. [PMID: 33987864 DOI: 10.1111/ced.14730] [Reference Citation Analysis]
159 Stadler R, Assaf C, Klemke C, Nashan D, Weichenthal M, Dummer R, Sterry W. Brief S2k guidelines - Cutaneous lymphomas: Cutaneous lymphomas. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2013;11:19-28. [DOI: 10.1111/ddg.12015_5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
160 Hruska CJ, Bertoli RJ, Young YD, Burkhart PH, Googe PB. Primary cutaneous anaplastic large cell lymphoma in a patient receiving adalimumab. JAAD Case Rep 2015;1:56-9. [PMID: 27051683 DOI: 10.1016/j.jdcr.2014.12.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
161 Yi S, Sun J, Qiu L, Fu W, Wang A, Liu X, Yang Y, Kadin ME, Tu P, Wang Y. Dual Role of EZH2 in Cutaneous Anaplastic Large Cell Lymphoma: Promoting Tumor Cell Survival and Regulating Tumor Microenvironment. Journal of Investigative Dermatology 2018;138:1126-36. [DOI: 10.1016/j.jid.2017.10.036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
162 Kadin ME, Deva A, Xu H, Morgan J, Khare P, MacLeod RA, Van Natta BW, Adams WP Jr, Brody GS, Epstein AL. Biomarkers Provide Clues to Early Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma. Aesthet Surg J 2016;36:773-81. [PMID: 26979456 DOI: 10.1093/asj/sjw023] [Cited by in Crossref: 97] [Cited by in F6Publishing: 89] [Article Influence: 16.2] [Reference Citation Analysis]
163 Martires KJ, Cohen BE, Cassarino DS. CD30+ lymphoproliferative disorder with spindle-cell morphology: Lymphomatoid papulosis with spindle-cell morphology. J Cutan Pathol 2016;43:1041-4. [DOI: 10.1111/cup.12773] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
164 Ferenczi K, Makkar HS. Cutaneous lymphoma: Kids are not just little people. Clinics in Dermatology 2016;34:749-59. [DOI: 10.1016/j.clindermatol.2016.07.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
165 Martinez-Cabriales SA, Walsh S, Sade S, Shear NH. Lymphomatoid papulosis: an update and review. J Eur Acad Dermatol Venereol 2020;34:59-73. [PMID: 31494989 DOI: 10.1111/jdv.15931] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
166 Philippe E, Creech KT, Cook N, Segura J. Recurrent Primary Cutaneous Anaplastic Large Cell Lymphoma With Systemic Involvement: A Case Report and Literature Review. Cureus 2021;13:e14284. [PMID: 33968499 DOI: 10.7759/cureus.14284] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
167 Zinzani PL, Bonthapally V, Huebner D, Lutes R, Chi A, Pileri S. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas. Crit Rev Oncol Hematol 2016;99:228-40. [PMID: 26811014 DOI: 10.1016/j.critrevonc.2015.12.018] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
168 Ba W, Yin G, Yang J, Zhang Z, Wang W, Zhao Z, Chen H, Li C. Lymphomatoid papulosis type E with a CD56+ immunophenotype presenting with purpura‐like lesions. J Cutan Pathol 2019;46:542-5. [DOI: 10.1111/cup.13472] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
169 Kempf W, Mitteldorf C, Karai LJ, Robson A. Lymphomatoid papulosis - making sense of the alphabet soup: a proposal to simplify terminology: Lymphomatoid papulosis - terminology. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2017;15:390-4. [DOI: 10.1111/ddg.13207] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
170 Kacerovska D, Michal M, Kazakov DV. Pediatric Case of Primary Cutaneous Eosinophil-Rich CD30+ Anaplastic Large-Cell Lymphoma With Follicular Mucinosis. The American Journal of Dermatopathology 2014;36:e78-80. [DOI: 10.1097/dad.0b013e3182914c89] [Cited by in Crossref: 6] [Article Influence: 0.8] [Reference Citation Analysis]
171 Porcu P, Sahu J. A positive randomised trial in cutaneous T-cell lymphoma. Lancet 2017;390:533-4. [PMID: 28600131 DOI: 10.1016/S0140-6736(17)31473-3] [Reference Citation Analysis]
172 Sica A, Vitiello P, Sorriento A, Ronchi A, Calogero A, Sagnelli C, Troiani T, Fasano M, Dodaro CA, Franco R, Casale B, Santangelo M, Ciccozzi M, Ciardiello F, Argenziano G, Moscarella E. Lymphomatoid papulosis. Minerva Med 2020;111:166-72. [PMID: 31958921 DOI: 10.23736/S0026-4806.19.06395-X] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
173 Sun J, Yi S, Qiu L, Fu W, Wang A, Liu F, Wang L, Wang T, Chen H, Wang L, Kadin ME, Tu P, Wang Y. SATB1 Defines a Subtype of Cutaneous CD30+ Lymphoproliferative Disorders Associated with a T-Helper 17 Cytokine Profile. Journal of Investigative Dermatology 2018;138:1795-804. [DOI: 10.1016/j.jid.2018.02.028] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
174 Meconi F, Secchi R, Palmieri R, Vaccarini S, Rapisarda VM, Giannì L, Esposito F, Provenzano I, Nasso D, Pupo L, Cantonetti M. Primary Cutaneous Anaplastic Large Cell Lymphoma of the Oral Cavity Successfully Treated with Brentuximab Vedotin. Case Rep Hematol 2019;2019:9651207. [PMID: 31637066 DOI: 10.1155/2019/9651207] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
175 Merli M, Ferrario A, Maffioli M, Olivares C, Stasia A, Arcaini L, Passamonti F. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma. Expert Review of Hematology 2016;9:767-80. [DOI: 10.1080/17474086.2016.1205949] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
176 Noe MH, Drake A, Link BK, Liu V. Papular mycosis fungoides: report of two patients, literature review, and conceptual re-appraisal. J Cutan Pathol. 2013;40:714-719. [PMID: 23651057 DOI: 10.1111/cup.12161] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
177 Dippel E, Assaf C, Becker JC, von Bergwelt-baildon M, Beyer M, Cozzio A, Eich HT, Follmann M, Grabbe S, Hillen U, Klapper W, Klemke C, Lamos C, Loquai C, Meiß F, Mestel D, Nashan D, Nicolay JP, Oschlies I, Schlaak M, Stoll C, Vag T, Weichenthal M, Wobser M, Stadler R. S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 2: Treatment and Follow-up (ICD10 C82 - C86): German guidelines for cutaneous lymphomas. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2018;16:112-22. [DOI: 10.1111/ddg.13401] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
178 Cui H, Liu J, Li L, Ren J, Guo S, Bai L. Analysis of differential β variable region of T cell receptor expression and NAV3/TNFRSF1B gene mutation in mycosis fungoides. Oncotarget 2016;7:17986-90. [PMID: 26918607 DOI: 10.18632/oncotarget.7673] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
179 Ganapathi KA, Pittaluga S, Odejide OO, Freedman AS, Jaffe ES. Early lymphoid lesions: conceptual, diagnostic and clinical challenges. Haematologica 2014;99:1421-32. [PMID: 25176983 DOI: 10.3324/haematol.2014.107938] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 5.7] [Reference Citation Analysis]
180 Kheterpal M, Mehta-Shah N, Virmani P, Myskowski PL, Moskowitz A, Horwitz SM. Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides. Curr Hematol Malig Rep 2016;11:224-33. [PMID: 27101016 DOI: 10.1007/s11899-016-0322-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
181 Lee GH, Bae GH, Rieger KE, Kim YH, Chiou AS. Angiodestructive lymphomatoid papulosis lasting more than 45 years. JAAD Case Rep 2019;5:767-9. [PMID: 31516992 DOI: 10.1016/j.jdcr.2019.06.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
182 Fujimura T, Lyu C, Tsuchiyama K, Aiba S. CD30-Positive Angioinvasive Lymphomatoid Papulosis (Type E) Developing from Parapsoriasis en Plaque. Case Rep Oncol 2018;11:850-4. [PMID: 30687061 DOI: 10.1159/000495689] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
183 Fujii K. New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma. Front Oncol 2018;8:198. [PMID: 29915722 DOI: 10.3389/fonc.2018.00198] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
184 Partarrieu‐mejías F, García‐legaz‐martínez M, Martínez‐domenech Á, Hernández‐bel P, Alegre‐de Miquel V, Pérez‐ferriols A. Methotrexate‐resistant acral lymphomatoid papulosis with complete remission after psoralen‐ultraviolet A therapy. Dermatologic Therapy 2020;33. [DOI: 10.1111/dth.13782] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
185 Humme D, Möbs M, Pullmann S, Haidar A, Beyer M, Sterry W, Assaf C. Maligne Lymphome der Haut: Update zu Diagnostik und Therapie kutaner T-Zell-Lymphome. Hautarzt 2012;63:423-36. [DOI: 10.1007/s00105-012-2387-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
186 Miquel J, Vourc'h-jourdain M, Thomas C, Cassagnau E, Stalder J, Barbarot S. Relapsing lymphomatoid papulosis after allogenic bone-marrow transplant. Clin Exp Dermatol 2013;38:741-4. [DOI: 10.1111/ced.12101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
187 Nikolaenko L, Zain J, Rosen ST, Querfeld C. CD30-Positive Lymphoproliferative Disorders. In: Querfeld C, Zain J, Rosen ST, editors. T-Cell and NK-Cell Lymphomas. Cham: Springer International Publishing; 2019. pp. 249-68. [DOI: 10.1007/978-3-319-99716-2_12] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
188 Melchers R, Willemze R, Bekkenk M, de Haas E, Horvath B, van Rossum M, Sanders C, Veraart J, Vermeer M, Quint K. Evaluation of treatment results in multifocal primary cutaneous anaplastic large cell lymphoma: report of the Dutch Cutaneous Lymphoma Group. Br J Dermatol 2018;179:724-31. [DOI: 10.1111/bjd.16501] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
189 Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Beyer M, Cozzio A, Eich HT, Follmann M, Grabbe S, Hillen U, Klapper W, Klemke CD, Lamos C, Loquai C, Meiß F, Mestel D, Nashan D, Nicolay JP, Oschlies I, Schlaak M, Stoll C, Vag T, Weichenthal M, Wobser M, Stadler R. S2k-Leitlinie - Kutane Lymphome Update 2016 - Teil 2: Therapie und Nachsorge (ICD10 C82 - C86). J Dtsch Dermatol Ges 2018;16:112-23. [PMID: 29314698 DOI: 10.1111/ddg.13401_g] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
190 Melchers RC, Willemze R, Vermaat JSP, Jansen PM, Daniëls LA, Putter H, Bekkenk MW, de Haas ERM, Horvath B, van Rossum MM, Sanders CJG, Veraart JCJM, Vermeer MH, Quint KD. Outcomes of rare patients with a primary cutaneous CD30+ lymphoproliferative disorder developing extracutaneous disease. Blood 2020;135:769-73. [PMID: 31977038 DOI: 10.1182/blood.2019002799] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
191 Wohlmuth-Wieser I. Primär kutane T-Zell-Lymphome im Kindes- und Jugendalter. J Dtsch Dermatol Ges 2021;19:563-83. [PMID: 33861014 DOI: 10.1111/ddg.14509_g] [Reference Citation Analysis]
192 Trautinger F. Phototherapy of cutaneous T-cell lymphomas. Photochem Photobiol Sci 2018;17:1904-12. [PMID: 30325389 DOI: 10.1039/c8pp00170g] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
193 Wehkamp U, Weichenthal M. [Treatment of rare cutaneous T‑cell lymphoma and blastic plasmacytoid dendritic cell neoplasm]. Hautarzt 2017;68:711-5. [PMID: 28795194 DOI: 10.1007/s00105-017-4024-2] [Reference Citation Analysis]
194 Samols MA, Su A, Ra S, Cappel MA, Louissant A, Knudson RA, Ketterling RP, Said J, Binder S, Harris NL, Feldman AL, Kim J, Kim YH, Gratzinger D. Intralymphatic Cutaneous Anaplastic Large Cell Lymphoma/Lymphomatoid Papulosis: Expanding the Spectrum of CD30-positive Lymphoproliferative Disorders. American Journal of Surgical Pathology 2014;38:1203-11. [DOI: 10.1097/pas.0000000000000217] [Cited by in Crossref: 31] [Cited by in F6Publishing: 3] [Article Influence: 3.9] [Reference Citation Analysis]
195 Specht L, Dabaja B, Illidge T, Wilson LD, Hoppe RT; International Lymphoma Radiation Oncology Group. Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2015;92:32-9. [PMID: 25863751 DOI: 10.1016/j.ijrobp.2015.01.008] [Cited by in Crossref: 90] [Cited by in F6Publishing: 69] [Article Influence: 12.9] [Reference Citation Analysis]
196 Lim HLJ, Tan EST, Tee SI, Ho ZY, Boey JJJ, Tan WP, Tang MBY, Shen L, Chan YH, Tan SH. Epidemiology and prognostic factors for mycosis fungoides and Sézary syndrome in a multi-ethnic Asian cohort: a 12-year review. J Eur Acad Dermatol Venereol 2019;33:1513-21. [PMID: 30801779 DOI: 10.1111/jdv.15526] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
197 Rasmussen TA, McMahon J, Chang JJ, Symons J, Roche M, Dantanarayana A, Okoye A, Hiener B, Palmer S, Lee WS, Kent SJ, Van Der Weyden C, Prince HM, Cameron PU, Lewin SR. Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome. AIDS 2017;31:1839-45. [PMID: 28514279 DOI: 10.1097/QAD.0000000000001540] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
198 Gao C, Harrop S, Van Der Weyden C, McCormack C, Prince HM. Primary cutaneous anaplastic large cell lymphoma and evolving clinical practice: 26 years of skin lesions with locoregional progression to systemic disease. Leuk Lymphoma 2020;61:2268-70. [PMID: 32397855 DOI: 10.1080/10428194.2020.1761972] [Reference Citation Analysis]
199 Kempf W, Kazakov DV, Kerl K. Cutaneous Lymphomas: An Update. Part 1 T-Cell and Natural Killer/T-Cell Lymphomas and Related Conditions. The American Journal of Dermatopathology 2014;36:105-23. [DOI: 10.1097/dad.0b013e318289b1db] [Cited by in Crossref: 37] [Cited by in F6Publishing: 4] [Article Influence: 4.6] [Reference Citation Analysis]
200 Dobos G, Battistella M, Jouenne F, Mourah S, Vignon-Pennamen MD, Ram-Wolff C, Herms F, Dauendorffer JN, Rivet J, Cayuela JM, Bouaziz D, Brice P, Lebbé C, Bagot M, de Masson A. Challenges in the diagnosis of primary cutaneous CD30+ anaplastic large-cell lymphoma. Br J Dermatol 2020;182:233-4. [PMID: 31278742 DOI: 10.1111/bjd.18328] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
201 Barbé J, Escobar G, Marzouki-Zerouali A, Lardenois E, Schmutz JL, Bursztejn AC. Disseminated indolent ALK-positive primary cutaneous anaplastic large cell lymphoma (C-ALCL) lasting for 10 years. Int J Dermatol 2021;60:e146-7. [PMID: 33249555 DOI: 10.1111/ijd.15324] [Reference Citation Analysis]
202 Nicolae-Cristea AR, Benner MF, Zoutman WH, van Eijk R, Jansen PM, Tensen CP, Willemze R. Diagnostic and prognostic significance of CDKN2A/CDKN2B deletions in patients with transformed mycosis fungoides and primary cutaneous CD30-positive lymphoproliferative disease. Br J Dermatol 2015;172:784-8. [PMID: 25308604 DOI: 10.1111/bjd.13476] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
203 Hibler J, Salavaggione AL, Martin A, Gru AA. A unique case of concurrent chronic lymphocytic leukemia/small lymphocytic lymphoma and lymphomatoid papulosis in the same biopsy. J Cutan Pathol 2015;42:276-84. [PMID: 25382820 DOI: 10.1111/cup.12435] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
204 Gentile MS, Martinez-Escala ME, Thomas TO, Guitart J, Rosen S, Kuzel T, Mittal BB. Single-Fraction Radiotherapy for CD30(+) Lymphoproliferative Disorders. Biomed Res Int 2015;2015:629587. [PMID: 26504818 DOI: 10.1155/2015/629587] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
205 González-lópez MA, González-vela MDC, Caballero C, Consuegra G, Fernández-llaca H, Piris MA. Localized lymphomatoid papulosis. Int J Dermatol 2015;54:e98-e100. [DOI: 10.1111/ijd.12719] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
206 Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, Talpur R. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. J Clin Oncol 2015;33:3759-65. [PMID: 26261247 DOI: 10.1200/JCO.2014.60.3787] [Cited by in Crossref: 176] [Cited by in F6Publishing: 47] [Article Influence: 25.1] [Reference Citation Analysis]
207 Leduc C, Blandino IIP, Alhejaily A, Baetz T, Good DJ, Farmer PL, Squire JA, Lebrun DP. Composite Mantle Cell and Primary Cutaneous Anaplastic Large Cell Lymphoma: Case Report and Review of the Literature. The American Journal of Dermatopathology 2015;37:232-6. [DOI: 10.1097/dad.0000000000000233] [Cited by in Crossref: 6] [Article Influence: 0.9] [Reference Citation Analysis]